181 related articles for article (PubMed ID: 24258993)
1. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
[TBL] [Abstract][Full Text] [Related]
3. A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U; Samuels Y
Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
[TBL] [Abstract][Full Text] [Related]
4. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM; Li W; Guan YX; Zhang X; Chen XC; Ding Y; Wen XZ; Peng RQ; Yan SM; Zhang XS
Chin J Cancer; 2013 Jul; 32(7):410-4. PubMed ID: 23237222
[TBL] [Abstract][Full Text] [Related]
5. Non-reproducible sequence artifacts in FFPE tissue: an experience report.
Ofner R; Ritter C; Ugurel S; Cerroni L; Stiller M; Bogenrieder T; Solca F; Schrama D; Becker JC
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1199-1207. PubMed ID: 28314930
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
[TBL] [Abstract][Full Text] [Related]
7. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
Takahashi Y; Fukuda Y; Yoshimura J; Toyoda A; Kurppa K; Moritoyo H; Belzil VV; Dion PA; Higasa K; Doi K; Ishiura H; Mitsui J; Date H; Ahsan B; Matsukawa T; Ichikawa Y; Moritoyo T; Ikoma M; Hashimoto T; Kimura F; Murayama S; Onodera O; Nishizawa M; Yoshida M; Atsuta N; Sobue G; ; Fifita JA; Williams KL; Blair IP; Nicholson GA; Gonzalez-Perez P; Brown RH; Nomoto M; Elenius K; Rouleau GA; Fujiyama A; Morishita S; Goto J; Tsuji S
Am J Hum Genet; 2013 Nov; 93(5):900-5. PubMed ID: 24119685
[TBL] [Abstract][Full Text] [Related]
8. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Chakroborty D; Ojala VK; Knittle AM; Drexler J; Tamirat MZ; Ruzicka R; Bosch K; Woertl J; Schmittner S; Elo LL; Johnson MS; Kurppa KJ; Solca F; Elenius K
Cancer Res Commun; 2022 Jan; 2(1):10-27. PubMed ID: 36860695
[TBL] [Abstract][Full Text] [Related]
9. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
10. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia.
Law AJ; Kleinman JE; Weinberger DR; Weickert CS
Hum Mol Genet; 2007 Jan; 16(2):129-41. PubMed ID: 17164265
[TBL] [Abstract][Full Text] [Related]
11. Novel somatic mutations to PI3K pathway genes in metastatic melanoma.
Shull AY; Latham-Schwark A; Ramasamy P; Leskoske K; Oroian D; Birtwistle MR; Buckhaults PJ
PLoS One; 2012; 7(8):e43369. PubMed ID: 22912864
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
13. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
14. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
15. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation.
Muraoka-Cook RS; Sandahl M; Hunter D; Miraglia L; Earp HS
Mol Endocrinol; 2008 Oct; 22(10):2307-21. PubMed ID: 18653779
[TBL] [Abstract][Full Text] [Related]
16. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
Cullum RL; Lucas LM; Senfeld JI; Piazza JT; Neel LT; Whig K; Zhai L; Harris MH; Rael CC; Taylor DC; Cook LJ; Kaufmann DP; Mill CP; Jacobi MA; Smith FT; Suto M; Bostwick R; Gupta RB; David AE; Riese Ii DJ
PLoS One; 2020; 15(12):e0243901. PubMed ID: 33378376
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
18. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
[TBL] [Abstract][Full Text] [Related]
20. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
